ZLAB
Zai Lab Limited
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Buy
+46/100
Last price
25.50
▼ 0.12 (0.47%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
26.41
Prev close
25.62
Day high
26.92
Day low
25.51
Volume
1.21M
Market cap
$2.87B
P/E (TTM)
—
52W range
15.96 – 33.97
Day trading desk
Gap from prior close
+3.08%
Prior close 25.62
VWAP
25.68
-0.71% from price
Relative volume
3.64×
Unusually busy
Session range
9.88%
24.50 – 26.92
Position in range
41%
Mid range
ATR (14D)
1.15
4.52% of price
Prior day high
25.65
PDH
Prior day low
24.33
PDL
Bid / ask spread
—
Quote not published
Session volume
3.46M
Avg 951.94K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-1.35%
-3.3%
1M
-2.48%
-3.6%
3M
+29.52%
+25.0%
6M
+21.81%
+3.6%
YTD
+45.01%
+30.8%
1Y
-24.21%
-40.6%
3Y
+5.22%
-77.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on ZLAB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+586.68K
Net buying
Buy transactions
18
855.04K shares
Sell transactions
16
268.36K shares
Net transactions
+34
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
2.38M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 19, 26 | CHEN YAJING Chief Financial Officer |
SELL | 260 | $7.02K | Direct |
| Aug 14, 26 | CHEN YAJING Chief Financial Officer |
— | 1.25K | — | Direct |
| Aug 12, 26 | LIS WILLIAM DAVID Director |
SELL | 8.51K | $212.65K | Direct |
| Aug 11, 26 | CHEN YAJING Chief Financial Officer |
SELL | 619 | $15.47K | Direct |
| Jul 2, 26 | DU YING SAMANTHA Chief Executive Officer |
— | 29.05K | — | Direct |
| Jul 1, 26 | GAYNOR RICHARD BRIAN M.D. Director |
BUY | 1.74K | $33.07K | Direct |
| Jun 30, 26 | DU YING SAMANTHA Chief Executive Officer |
SELL | 7.03K | $130.22K | Direct |
| Jun 29, 26 | DU YING SAMANTHA Chief Executive Officer |
— | 17.97K | — | Direct |
| Jun 26, 26 | EDMONDSON FRAZOR TITUS III Officer |
SELL | 4.10K | $71.64K | Direct |
| Jun 26, 26 | CHEN YAJING Chief Financial Officer |
SELL | 2.26K | $39.53K | Direct |
| Jun 26, 26 | DU YING SAMANTHA Chief Executive Officer |
SELL | 24.54K | $428.55K | Direct |
| Jun 25, 26 | EDMONDSON FRAZOR TITUS III Officer |
— | 14.60K | — | Direct |
| Jun 25, 26 | CHEN YAJING Chief Financial Officer |
— | 6.25K | — | Direct |
| Jun 25, 26 | DU YING SAMANTHA Chief Executive Officer |
— | 58.80K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AMADO RAFAEL |
President | 57.02K | Sale |
DIEKMAN JOHN DAVID |
Director | 122.14K | Stock Award(Grant) |
DU YING SAMANTHA |
Chief Executive Officer | 1.22M | Conversion of Exercise of derivative security |
GAYNOR RICHARD BRIAN M.D. |
Director | 80.74K | Purchase |
LEUNG NISA BERNICE WING-YU |
Director | 96.30K | Stock Award(Grant) |
MOULDER LEON OLIVER JR. |
Director | 94.97K | Stock Award(Grant) |
SMILEY JOSHUA L |
President | 117.60K | Sale |
VOUNATSOS MICHEL PERICLES |
Director | 72.79K | Stock Award(Grant) |
WIRTH PETER KARL J.D. |
Director | 416.12K | Stock Award(Grant) |
YING DU |
Chief Executive Officer | 526.03K | Sale |
Fundamentals
Market cap$2.87B
Enterprise value$2.51B
Revenue (TTM)$449.61M
Gross profit$16.98M
EBITDA$-248.17M
Net income$-188.21M
EPS (TTM)$-1.70
Free cash flow$-83.96M
Total cash$617.52M
Total debt$254.58M
Book value / share$5.41
Shares outstanding112.27M
Float97.11M
Short % of float7.41%
Dividend yield0.00%
Beta (5Y)0.72
Valuation & profitability ratios
Trailing P/E—
Forward P/E-12.12
PEG ratio—
Price / sales—
Price / book4.73
EV / revenue5.58
EV / EBITDA-10.11
Gross margin3.78%
Operating margin-71.95%
Profit margin-41.86%
Return on equity-26.91%
Return on assets-14.74%
Debt / equity41.94
Current ratio2.13
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $460.16M | $398.99M | $266.72M | $215.04M | +15.3% |
| Operating revenue | $499.21M | $425.23M | $298.91M | $236.38M | +17.4% |
| Cost of revenue | $191.08M | $147.86M | $95.82M | $74.02M | +29.2% |
| Gross profit | $269.07M | $251.13M | $170.90M | $141.02M | +7.1% |
| Research & development | $220.90M | $234.50M | $265.87M | $286.41M | -5.8% |
| Selling, general & admin | $277.61M | $298.74M | $281.61M | $258.97M | -7.1% |
| Total operating expense | $492.65M | $525.08M | $545.04M | $533.91M | -6.2% |
| Operating income | -$223.57M | -$273.95M | -$374.14M | -$392.89M | +18.4% |
| Net interest income | $27.84M | $34.85M | $39.80M | $14.58M | -20.1% |
| Pre-tax income | -$178.46M | -$257.10M | -$334.62M | -$443.06M | +30.6% |
| Tax provision | -$2.93M | $0 | $0 | $0 | — |
| Net income | -$175.54M | -$257.10M | -$334.62M | -$443.29M | +31.7% |
| Net income to common | -$175.54M | -$257.10M | -$334.62M | -$443.29M | +31.7% |
| Basic EPS | -1.60 | -2.60 | -3.50 | -4.60 | +38.5% |
| Diluted EPS | -1.60 | -2.60 | -3.50 | -4.60 | +38.5% |
| EBIT | -$173.25M | -$254.85M | -$334.62M | -$443.06M | +32.0% |
| EBITDA | -$158.25M | -$242.99M | -$325.59M | -$434.84M | +34.9% |
| Basic shares | 109.53M | 98.95M | 96.64M | 95.81M | +10.7% |
| Diluted shares | 109.53M | 98.95M | 96.64M | 95.81M | +10.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $679.57M | $449.67M | $790.15M | $1.01B | +51.1% |
| Cash & short-term investments | $689.57M | $779.67M | $806.45M | $1.01B | -11.6% |
| Accounts receivable | $106.12M | $85.18M | $59.20M | $39.96M | +24.6% |
| Inventory | $74.75M | $39.88M | $44.83M | $31.62M | +87.4% |
| Total current assets | $1.02B | $1.05B | $939.61M | $1.12B | -3.0% |
| Property, plant & equipment | $66.54M | $69.46M | $68.69M | $78.77M | -4.2% |
| Goodwill & intangibles | $79.00M | $58.93M | $16.46M | $8.40M | +34.0% |
| Total assets | $1.17B | $1.19B | $1.04B | $1.22B | -1.1% |
| Total current liabilities | $416.17M | $299.38M | $203.07M | $139.84M | +39.0% |
| Current debt | $204.53M | $131.71M | — | — | +55.3% |
| Total debt | $224.26M | $153.47M | $15.15M | $20.39M | +46.1% |
| Total liabilities | $456.88M | $344.86M | $240.18M | $174.54M | +32.5% |
| Retained earnings | -$2.63B | -$2.45B | -$2.20B | -$1.86B | -7.2% |
| Shareholder equity | $715.50M | $840.90M | $796.12M | $1.05B | -14.9% |
| Working capital | $603.12M | $751.10M | $736.54M | $984.49M | -19.7% |
| Net tangible assets | $636.50M | $781.96M | $779.66M | $1.04B | -18.6% |
| Shares issued | 1.11B | 1.08B | 977.15M | 962.46M | +2.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$175.54M | -$257.10M | -$334.62M | -$443.29M | +31.7% |
| Depreciation & amortisation | $15.01M | $11.86M | $9.03M | $8.23M | +26.6% |
| Stock-based compensation | $65.60M | $70.65M | $79.63M | $61.30M | -7.2% |
| Change in working capital | -$54.71M | -$68.39M | $39.61M | -$66.25M | +20.0% |
| Operating cash flow | -$150.79M | -$214.87M | -$198.18M | -$367.64M | +29.8% |
| Capital expenditure | -$13.42M | -$61.52M | -$8.49M | -$24.98M | +78.2% |
| Investing cash flow | $307.87M | -$375.19M | -$10.78M | $420.02M | +182.1% |
| Financing cash flow | $72.35M | $349.89M | -$6.43M | -$1.73M | -79.3% |
| Free cash flow | -$164.21M | -$276.39M | -$206.67M | -$392.63M | +40.6% |
| End cash position | $780.69M | $550.78M | $791.26M | $1.01B | +41.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $106.31M | $99.61M | $127.60M | $116.09M | $109.98M | +6.7% |
| Operating revenue | $114.23M | $106.31M | $140.78M | $127.84M | $117.42M | +7.5% |
| Cost of revenue | $48.16M | $38.34M | $62.33M | $46.88M | $43.22M | +25.6% |
| Gross profit | $58.15M | $61.28M | $65.27M | $69.21M | $66.76M | -5.1% |
| Research & development | $61.77M | $65.59M | $61.63M | $47.93M | $50.61M | -5.8% |
| Selling, general & admin | $72.87M | $65.07M | $73.04M | $70.11M | $71.04M | +12.0% |
| Total operating expense | $134.64M | $130.56M | $133.53M | $117.18M | $121.65M | +3.1% |
| Operating income | -$76.49M | -$69.28M | -$68.26M | -$47.97M | -$54.90M | -10.4% |
| Net interest income | $4.29M | $4.81M | $5.89M | $6.95M | $7.58M | -10.8% |
| Pre-tax income | -$51.85M | -$49.58M | -$53.34M | -$35.96M | -$40.73M | -4.6% |
| Tax provision | -$1.02M | $1.44M | -$2.93M | $0 | $0 | -171.0% |
| Net income | -$50.83M | -$51.02M | -$50.41M | -$35.96M | -$40.73M | +0.4% |
| Net income to common | -$50.83M | -$51.02M | -$50.41M | -$35.96M | -$40.73M | +0.4% |
| Basic EPS | -0.50 | -0.50 | -0.50 | -0.30 | -0.40 | 0.0% |
| Diluted EPS | -0.50 | -0.50 | -0.50 | -0.30 | -0.40 | 0.0% |
| EBIT | -$50.26M | -$47.94M | -$51.98M | -$34.56M | -$39.47M | -4.8% |
| EBITDA | -$46.09M | -$43.99M | -$48.06M | -$30.66M | -$35.73M | -4.8% |
| Basic shares | 111.70M | 110.74M | 110.61M | 110.21M | 109.19M | +0.9% |
| Diluted shares | 111.70M | 110.74M | 110.61M | 110.21M | 109.19M | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $607.52M | $651.32M | $679.57M | $717.15M | $732.16M | -6.7% |
| Cash & short-term investments | $617.52M | $661.32M | $689.57M | $717.15M | $732.16M | -6.6% |
| Accounts receivable | $69.59M | $54.07M | $106.12M | $85.38M | $88.50M | +28.7% |
| Inventory | $90.89M | $85.96M | $74.75M | $67.14M | $61.70M | +5.7% |
| Total current assets | $914.04M | $944.73M | $1.02B | $1.03B | $1.03B | -3.2% |
| Property, plant & equipment | $62.59M | $64.65M | $66.54M | $64.62M | $66.95M | -3.2% |
| Goodwill & intangibles | $88.66M | $78.63M | $79.00M | $58.13M | $59.38M | +12.8% |
| Total assets | $1.07B | $1.10B | $1.17B | $1.16B | $1.16B | -1.9% |
| Total current liabilities | $428.58M | $392.98M | $416.17M | $359.77M | $331.50M | +9.1% |
| Current debt | $238.10M | $213.82M | $204.53M | $203.03M | $174.51M | +11.4% |
| Total debt | $254.58M | $231.91M | $224.26M | $219.36M | $191.40M | +9.8% |
| Total liabilities | $467.76M | $433.76M | $456.88M | $399.00M | $372.37M | +7.8% |
| Retained earnings | -$2.73B | -$2.68B | -$2.63B | -$2.58B | -$2.54B | -1.9% |
| Shareholder equity | $607.04M | $661.98M | $715.50M | $759.95M | $791.74M | -8.3% |
| Working capital | $485.45M | $551.75M | $603.12M | $673.18M | $702.56M | -12.0% |
| Net tangible assets | $518.38M | $583.35M | $636.50M | $701.82M | $732.36M | -11.1% |
| Shares issued | 1.13B | 1.12B | 1.11B | 1.11B | 1.10B | +1.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$50.83M | -$51.02M | -$50.41M | -$35.96M | -$40.73M | +0.4% |
| Depreciation & amortisation | $4.17M | $3.94M | $3.92M | $3.90M | $3.73M | +5.8% |
| Stock-based compensation | $11.94M | $13.52M | $15.90M | $16.92M | $16.97M | -11.7% |
| Change in working capital | -$19.74M | $35.87M | $2.33M | -$11.76M | -$10.34M | -155.1% |
| Operating cash flow | -$63.41M | -$11.91M | -$26.02M | -$32.04M | -$31.02M | -432.3% |
| Capital expenditure | -$1.46M | -$22.29M | -$1.30M | -$4.09M | -$4.17M | +93.4% |
| Investing cash flow | -$1.42M | -$22.29M | -$11.30M | -$4.05M | -$2.92M | +93.6% |
| Financing cash flow | $18.70M | $5.57M | -$430.00K | $20.79M | $8.85M | +235.6% |
| Free cash flow | -$64.87M | -$34.20M | -$27.32M | -$36.13M | -$35.20M | -89.7% |
| End cash position | $708.64M | $752.43M | $780.69M | $818.27M | $833.38M | -5.8% |
Options analytics
Put / call volume
0.95
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
15.00
-41.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
75
Contracts, this expiry
Put volume
71
Contracts, this expiry
Heaviest call OI
20.00
0 contracts
Heaviest put OI
15.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.68 | -0.46 | +32.3% |
| Mar 2026 | -0.53 | -0.46 | +12.6% |
| Dec 2025 | -0.42 | -0.46 | -8.5% |
| Sep 2025 | -0.29 | -0.33 | -12.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.56 | 6 | $108.82M | -6.3% |
| Next quarter | -0.62 | 6 | $113.62M | -11.0% |
| Current year | -2.20 | 10 | $436.47M | -5.1% |
| Next year | -2.11 | 10 | $552.13M | +26.5% |
Analyst targets & ownership
Mean target$33.14
High target$50.00
Low target$24.25
Implied upside29.96%
Analyst count12
ConsensusSTRONG BUY
Strong buy / Buy2 / 9
Hold1
Sell / Strong sell0 / 0
Held by insiders2.12%
Held by institutions38.46%
Institutions holding127
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
25.57
-0.27% from price
SMA 20
25.37
+0.81% from price
SMA 50
24.47
+4.52% from price
SMA 100
21.59
+18.10% from price
SMA 200
20.48
+24.91% from price
EMA 12
25.52
-0.07% from price
EMA 26
25.30
+0.78% from price
EMA 50
24.37
+4.62% from price
RSI (14)
52.1
Neutral
MACD (12,26,9)
0.22
Hist -0.13
ATR (14)
1.15
4.50% of price
Realised vol 30D
42.1%
Annualised
Bollinger upper
26.85
20, 2σ
Bollinger lower
23.90
20, 2σ
50 / 200 cross
Golden
24.47 vs 20.48
Trend bias
Above 200
+24.91%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.04
More volatile than market
Correlation to SPY
0.27
Largely independent
Realised vol 30D
42.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-51.6%
Peak to trough
Max drawdown 5Y
-87.0%
Peak to trough
ATR 14
1.15
4.50% of price
Beta (reported)
0.72
5Y monthly, from filing
Short interest
Shares short
8.16M
Prior 7.47M
Change vs prior
+9.3%
Shorts adding
% of float
7.41%
Normal
% of shares out
7.27%
Against total outstanding
Days to cover
8.1
Crowded exit
Float
97.11M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 26 | Citigroup | MAINTAINED | Buy | Buy |
| May 8, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Mar 18, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Feb 27, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Feb 5, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jan 7, 26 | UBS | INITIATED | — | Buy |
| Aug 11, 25 | Citigroup | MAINTAINED | Buy | Buy |
| Jun 30, 25 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Mar 27, 25 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Mar 13, 25 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Mar 7, 25 | Scotiabank | INITIATED | — | Sector Outperform |
| Mar 3, 25 | B of A Securities | DOWNGRADE | Buy | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-05-21
Periodic Financial Reports
10-Q · 2026-05-07
Annual Report to Shareholders
ARS · 2026-04-28
Proxy Statements
PRE 14A · 2026-04-17
Periodic Financial Reports
10-K · 2026-02-26
Corporate Changes & Voting Matters
8-K · 2025-11-06
Headlines
Asian Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading
MT Newswires · 16h ago
Is Zai Lab (ZLAB) Cheap After Its ESMO 2026 Lung Cancer Data Update?
Simply Wall St. · 3d ago
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading; End Week Flat
MT Newswires · 5d ago
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Business Wire · 8d ago
Asian Equities Traded in the US as American Depositary Receipts Fall in Thursday Trading
MT Newswires · 13d ago
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool · 13d ago
Big Pharma Is Pouring Billions Into China’s Biotechs
Barrons.com · 23d ago
Zai Lab (ZLAB) Stock Looks Stretched On Sales But Reasonable On Broader Checks
Simply Wall St. · 31d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.